Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection
Language English Country Poland Media print-electronic
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
Grant support
R24 DK064400
NIDDK NIH HHS - United States
DK047322
NIDDK NIH HHS - United States
DK064400
NIDDK NIH HHS - United States
AI078477
NIAID NIH HHS - United States
- MeSH
- Antigenic Variation MeSH
- HIV Infections immunology therapy virology MeSH
- HIV-1 pathogenicity physiology MeSH
- Humans MeSH
- Antibodies, Neutralizing MeSH
- Polysaccharides immunology metabolism MeSH
- Virus Attachment MeSH
- Viral Envelope Proteins immunology metabolism MeSH
- AIDS Vaccines MeSH
- Virulence MeSH
- Antiretroviral Therapy, Highly Active * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Research Support, N.I.H., Extramural MeSH
- Names of Substances
- Antibodies, Neutralizing MeSH
- Polysaccharides MeSH
- Viral Envelope Proteins MeSH
- AIDS Vaccines MeSH
Infection of host cells with HIV-1 depends on a highly glycosylated virus envelope glycoprotein (Env) and host-cell receptors. Glycans participate substantially in Env folding and in the binding of virions to the host-cell surface and indirectly affect cellular uptake of HIV-1. Moreover, Env glycans could protect HIV-1 from host's neutralizing antibodies, but some glycans, on the other hand, represent targets for neutralizing antibodies. Variability of Env and its glycans in the HIV-1 strains from around the world as well as in patients during disease progression contributes substantially to further HIV-1 spreading in spite of the progress in basic HIV-1 research, vaccine development, and highly active antiretroviral therapy of HIV-1 infections.
References provided by Crossref.org
Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women
